Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Müller MC, Hochhaus A, Haferlach T, Haferlach C: A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557-560. doi:10.1038/leu.2010.298. PMID: 21274004

Saussele S, Hehlmann R, Gratwohl A, Hochhaus A. Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors. Bone Marrow Transplant. 2012;47(2):304. doi:10.1038/bmt.2011.70. PMID: 21441956

le Coutre, Philipp D.; Giles, Francis J.; Hochhaus, Andreas; Apperley, Jane F.; Ossenkoppele, Gert J.; Blakesley, Rick; Shou, Yaping, Gallagher, Neil J.; Baccarani, Michele; Cortes, Jorge E.; Kantarjian, Hagop M.: Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia PMID: 22076466

Al-Batran S-E, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz R-D, Hartmann JT, Atmaca A, Altmannsbergeg H-M, Jäger E: The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 23 (7), 1699-1705. PMID: 22112973

Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC: Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in
Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. J Clin Oncol (2012). PMID: 23109697

Bohne S, Kentouche K, Petersen I, Fritzenwanger M, Pletz MW, Lehmberg K, La Roseé P, Guntinas-Lichius O: Fulminant Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis. The Laryngoscope (2012). PMID: 27496079

Brede-Hekimian K: Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer. The Lancet Oncology Vol. 379 (9833), 2237-2238. PMID: 22704161

Briest F, Berndt A, Clement J, Junker K, von Eggeling F, Grimm S, Friedrich K: Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology. Front Biosci (Elite Ed.) 2012, 1871-1887. PMID: 22202004             

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M,
Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M: Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup. J Clin Oncol 30 (29), 3604-3610. PMID: 22965967

Cross NCP, White H, Müller MC, Saglio G, Hochhaus A: Standardized definitions of molecular response in chronic
myeloid leukemia. Leukemia 2012, 26, 2172-2175. PMID: 22504141

Ernst T, Hochhaus A: Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Semin Oncol 39 (1), 58-66. PMID: 22289492

Ernst T, Pflug A, Rinke J, Ernst J, Bierbach U, Beck JF, Hochhaus A, Gruhn B: A somatic EZH2 mutation in a child with acute myeloid leukemia. Leukemia (2012).

Fuchs M, Reinhöfer M, Ragoschke-Schumm A, Sayer HG, Böer K, Witte OW, Hochhaus A, Axer H: Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC Blood Disorders (2012). PMID: 22871019             

Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon F-X, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG: Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012, 26 (5), 959-62. PMID: 22157807              

Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J, Lange T, Hochhaus A: Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 2012, 26 (1), 172-177. PMID: 21818112

Godfrey R, Bauer R, Stopp S, Müller JP, Heinrich T, Böhmer S-A, Dagnell M, Schnetzke U, Scholl S, Östman A, Böhmer F-D: Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ. Blood (2012). PMID: 22438257

Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann J-L, Zaritskey A, Hehlmann R: Definitions, methodological, and statistical issues for phase III clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood (2012). PMID: 22508936

Hanfstein B, Müller MC, Hehlmann R, Erben P, LausekerM, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb H-J, Krause SW, Hofmann W-K, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Sauele S, Hochhaus A: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26 (9), 2096-2102. PMID: 22446502

Hekimian K, Meisezahl S, Trompelt K, Rabenstein C, Pachmann K: Epithelial Cell Dissemination and Readhesion: Analysis of
Factors Contributing to Metastasis Formation in Breast Cancer. ISRN Oncology (Vol. 2012). PMID: 22530147

Hochhaus A, Ernst T, Ziermann J, Eigendorff E, La Rosée P: Chronische myeloische Leukämie Heilung durch medikamentöse Therapie? Der Onkologe 12 (2012), 1105-1114.

Hochhaus A, Müller MC, Lange T, Thiede C, Haferlach T: Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe. J Lab Med 2012, 36 (6), 405-411.

Hochhaus A, Reiter A, Ernst T, La Rosée P: Imatinib and Beyond - Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. Onkologie. 2012; 35 (Suppl 1), 34-41. PMID: 22286586

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Won Kim T, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L,
Fielding A, Robertson JD, Saunders MP: Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology (2012). PMID: 22965965

Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A: Chemoradiotherapy with capecitabine versus fl uorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. The Lancet Oncology (2012). PMID: 22503032

Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I: Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood (2012). PMID: 23175686

Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A,
Hughes TP, Saglio G, Radich JP, Kim D-W, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM: Prediction of outcomes in patients with Phþ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia (2012). PMID: 23174881

Jaenichen D, Brunkhorst FM, Strauss B, Rosendahl J: Physical and mental long-term sequelae following intensive care of severe sepsis in patients and relatives. Psychother Psychosom Med Psychol (2012) ,62 (9–10), 335–43. PMID: 22585583

Klag T, Härtel N, Erben P, Schwaab J, Schnetzke U, Schenk T, Hochhaus A, La Rosée P: Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common b-subunit c of cytokine receptors. Leukemia 2012, 26 (6), 1321-1328. PMID: 22289991

Klag T, Schnetzke U, Benz R, Zanow J, Glaser A, Pörner TC, Scholl S, Reiter A, Hochhaus A, La Rosée P: Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome. Ann Hematol (2012) 91, 139-141. PMID: 21494797

Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim D-W, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119 (5), 1123-1129. PMID: 22160483

Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A: Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012, 119 (2), 530-539. PMID: 22101898

Lange T, Ernst T, Gruber F, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M: The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica (2012). PMID: 23065514

Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim D-W, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012, 26, 2197-2203. PMID: 22699418

le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM: Nilotinib in patients with Phþ chronic myeloid leukemia in accelerated phase following imatinib resistance or  intolerance: 24-month follow-up results. Leukemia 2012, 26 (6), 1189-1194. PMID: 22076466

Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A: High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26, 2353-2359. PMID: 22504140              

Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NC, Hofmann WK, Reiter A: Limited  clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012, 26 (1), 162-164. PMID: 21818111

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MR, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T: Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012). PMID: 22411871              

Nikolajski M, Wotschadlo J, Clement JH, Heinze T: Amino-Functionalized Cellulose Nanoparticles: Preparation, Characterization, and Interactions with Living Cellsa . Macromolecular Bioscience 2012, 12, 920-925. PMID: 22535832

Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus H-U, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park K-S, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DAM, Snijders PJF, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Terje Brustugun O, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria J-C, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S,Thomas RK: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics (2012). PMID: 22941188

Rehnitz J, Hochhaus A, Schaffelder R, Erben P, Sütterlin M: Pregnancy and spontaneous delivery in a patient with primary myelofibrosis. Journal of Neonatal-Perinatal Medicine 5 (2012), 393-395.

Saußele S, Hehlmann R, Gratwohl  A, Hochhaus A: Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors. Bone Marrow Transplantation (2012) 47, 304. PMID: 21441956

Schmalenberg H: Zertifizierungsverfahren für Onkologische Zentren in Deutschland. Der Onkologe 2012 (18), 501-510.

Schwaab J, Ernst T, Erben P, Rinke J, Schnittger S, Ströbel P, Metzgeroth G, Mossner M, Haferlach T, Cross NCP, Hochhaus A, Hofmann W-K, Reiter A: Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Ann Hematol (2012). PMID: 23010802

Wotschadlo J, Liebert T, Clement JH, Anspach N, Höppener S, Rudolph T, Müller R, Schacher FH, Schubert US, Heinze T: Biocompatible Multishell Architecture for Iron Oxide Nanoparticles. Macromol Biosci (2012). PMID: 23161745

Yin OQP, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA: Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. (2012) PMID: 22623211

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer F-D, Hochhaus A, Fischer T, Scholl S: Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. British Journal of Haematology (2012), 1365-2141. PMID: 22409268